442 related articles for article (PubMed ID: 36248808)
1. Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment.
McRitchie BR; Akkaya B
Front Immunol; 2022; 13():940052. PubMed ID: 36248808
[TBL] [Abstract][Full Text] [Related]
2. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
5. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
6. Modulating Treg stability to improve cancer immunotherapy.
Kang JH; Zappasodi R
Trends Cancer; 2023 Nov; 9(11):911-927. PubMed ID: 37598003
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Yano H; Andrews LP; Workman CJ; Vignali DAA
Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
9. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 Signaling.
Son J; Cho JW; Park HJ; Moon J; Park S; Lee H; Lee J; Kim G; Park SM; Lira SA; Mckenzie AN; Kim HY; Choi CY; Lim YT; Park SY; Kim HR; Park SH; Shin EC; Lee I; Ha SJ
Cancer Immunol Res; 2020 Nov; 8(11):1393-1406. PubMed ID: 32878747
[TBL] [Abstract][Full Text] [Related]
13. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
14. Increased tumor-infiltrating CD45RA
Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
[TBL] [Abstract][Full Text] [Related]
15. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
16. Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy.
Zhou L; Velegraki M; Wang Y; Mandula JK; Chang Y; Liu W; Song NJ; Kwon H; Xiao T; Bolyard C; Hong F; Xin G; Ma Q; Rubinstein MP; Wen H; Li Z
J Clin Invest; 2024 May; ():. PubMed ID: 38787791
[TBL] [Abstract][Full Text] [Related]
17. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]